

Serial No.: 08/459,141
Filed: 2 June 1995

The Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1300 (Our Order No. A-54528-9/WHD).

Kindly amend the present application in the following respects:

In the Specification:

In the amendment filed by mailing on 1 May 1996 herein, a paragraph relating to priority lineage should have been, and hereby is, instructed to be entered on page 1 as a replacement of the current lineage paragraph appearing as the first paragraph.

On page 24, line 21, change "BglIII" to --Bgl II--.

In the Claims:

620
22. (Amended) The vaccine according to Claim 20 wherein said mixture comprises glycoprotein D [and additional effective glycoprotein].
722
28. (Amended) The vaccine according to Claim 22 wherein said mixture *722*
further comprises glycoprotein B [and glycoprotein D].

REMARKS

For the Examiner's convenience, the pending claims are attached in an Appendix.

Applicants wish to begin with a discussion about the art which has been considered in this case. In particular, an Information Disclosure Statement was mailed by Applicants 1 May 1996. Applicants have not received any notification